Related Experiment Video
Updated: May 12, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants
Ying-Xin Fan1, Lily Wong1, Michael P Marino2
1Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Bethesda, Maryland 20892.
Abstract:
Activating mutations in the αC-β4 loop of the ERBB2 kinase domain, such as ERBB2(YVMA) and ERBB2(G776VC), have been identified in human lung cancers and found to drive tumor formation. Here we observe that the docking protein GAB1 is hyper-phosphorylated in carcinomas from transgenic mice and in cell lines expressing these ERBB2 cancer mutants. Using dominant negative GAB1 mutants lacking canonical tyrosine residues for SHP2 and PI3K interactions or lentiviral shRNA that targets GAB1, we demonstrate that GAB1 phosphorylation is required for ERBB2 mutant-induced cell signaling, cell transformation, and tumorigenesis. An enzyme kinetic analysis comparing ERBB2(YVMA) to wild type using physiologically relevant peptide substrates reveals that ERBB2(YVMA) kinase adopts a striking preference for GAB1 phosphorylation sites as evidenced by ∼150-fold increases in the specificity constants (kcat/Km) for several GAB1 peptides, and this change in substrate selectivity was predominantly attributed to the peptide binding affinities as reflected by the apparent Km values. Furthermore, we demonstrate that ERBB2(YVMA) phosphorylates GAB1 protein ∼70-fold faster than wild type ERBB2 in vitro. Notably, the mutation does not significantly alter the Km for ATP or sensitivity to lapatinib, suggesting that, unlike EGFR lung cancer mutants, the ATP binding cleft of the kinase is not significantly changed. Taken together, our results indicate that the acquired substrate preference for GAB1 is critical for the ERBB2 mutant-induced oncogenesis.
Insights
Activating ERBB2 (Epidermal Growth Factor Receptor 2) mutations drive lung cancer by altering substrate preference. These ERBB2 mutants specifically phosphorylate GAB1, promoting tumor growth and signaling.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Activating mutations in ERBB2 (Epidermal Growth Factor Receptor 2) kinase domain, like ERBB2(YVMA), are implicated in lung cancer development.
- These mutations lead to uncontrolled cell signaling and tumor formation.
Purpose of the Study:
- To investigate the role of GAB1 (Grb2-associated binder 1) in ERBB2 mutant-driven tumorigenesis.
- To elucidate the mechanism by which ERBB2 mutants enhance GAB1 phosphorylation.
Main Methods:
- Utilized dominant-negative GAB1 mutants and lentiviral shRNA to assess GAB1's requirement in ERBB2 mutant signaling.
- Performed enzyme kinetic analysis to compare wild-type ERBB2 and ERBB2(YVMA) substrate specificity.
- Measured in vitro phosphorylation rates of GAB1 protein by ERBB2 variants.
Main Results:
- GAB1 hyper-phosphorylation is observed in ERBB2 mutant-expressing carcinomas and cell lines.
- GAB1 phosphorylation is essential for ERBB2 mutant-induced cell signaling, transformation, and tumorigenesis.
- ERBB2(YVMA) exhibits a significantly increased preference for GAB1 phosphorylation sites, with a ~150-fold higher specificity constant and ~70-fold faster in vitro phosphorylation rate compared to wild-type ERBB2.
Conclusions:
- Acquired substrate preference for GAB1 is a critical mechanism in ERBB2 mutant-driven oncogenesis.
- The ATP binding site and lapatinib sensitivity remain largely unchanged, distinguishing these mutants from EGFR lung cancer mutants.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
07:49Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
Related Concept Videos
Mitogens and the Cell Cycle
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Ras Gene
Ras is a superfamily...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Amplifying Signals via Enzymatic Cascade
MAPK Signaling Cascades